Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-07-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-2211PMID 23864164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis

  2012cited by this paper
• Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents

  2012cited by this paper
• Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

  2011cited by this paper
• PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo

  2011cited by this paper
• Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX

  2011influential reference
• Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

  2011cited by this paper
• MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells

  2011cited by this paper
• Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

  2011cited by this paper
• Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

  2010cited by this paper
• Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation.

  2010cited by this paper
• A stapled p53 helix overcomes HDMX-mediated suppression of p53.

  2010influential reference
• Stage-specific sensitivity to p53 restoration during lung cancer progression

  2010cited by this paper
• Selective activation of p53-mediated tumour suppression in high-grade tumours

  2010cited by this paper
• Therapeutic targeting of p53 by small molecules.

  2010influential reference
• SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

  2010cited by this paper
• CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

  2010cited by this paper
• p53 family: Therapeutic targets in neuroblastoma.

  2010cited by this paper
• WIP1 phosphatase at the crossroads of cancer and aging.

  2010cited by this paper
• Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

  2009cited by this paper
• Embryonal neural tumours and cell death

  2009influential reference
• Blinded by the Light: The Growing Complexity of p53.

  2009cited by this paper
• HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

  2009cited by this paper
• Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

  2009cited by this paper
• New therapeutic targets for the treatment of high‐risk neuroblastoma

  2009cited by this paper
• Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

  2009influential reference
• p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA

  2009cited by this paper
• MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.

  2009cited by this paper
• Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists

  2009cited by this paper
• Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

  2009influential reference
• Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

  2009cited by this paper
• Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.

  2008cited by this paper
• High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene

  2008cited by this paper
• [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2].

  2007influential reference
• Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line.

  2007cited by this paper
• Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome

  2007cited by this paper
• p53 determines multidrug sensitivity of childhood neuroblastoma.

  2007cited by this paper
• Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.

  2006influential reference
• The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

  2005cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

  2004cited by this paper
• Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

  2003cited by this paper
• Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

  2003cited by this paper
• PPM1D is a potential target for 17q gain in neuroblastoma.

  2003cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.

  2001cited by this paper
• Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

  2001cited by this paper
• DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

  1999cited by this paper
• A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

  1999influential reference
• MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.

  1997cited by this paper
• Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

  1997cited by this paper
• Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.

  1995cited by this paper

• Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma

  2025cites this paper
• Molecular regulation and therapeutic targeting of MYCN in neuroblastoma: a comprehensive review

  2025cites this paper
• TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

  2024cites this paper
• The Development of p53-Targeted Therapies for Human Cancers

  2023cites this paper
• USP8 inhibitor–induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma

  2022influential citation
• Should mutant TP53 be targeted for cancer therapy?

  2022cites this paper
• Decreased DNA Damage and Improved p53 Specificity of RITA Analogs

  2022cites this paper
• Investigation of the effects of the small molecule RITA in pediatric acute lymphoblastic leukemia

  2022influential citation
• ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells

  2022cites this paper
• MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1.

  2021cites this paper
• PPM1D Is a Therapeutic Target in Childhood Neural Tumors

  2021cites this paper
• Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.

  2021cites this paper
• Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents

  2021cites this paper
• E3 ubiquitin ligases: styles, structures and functions

  2021cites this paper
• Editor's Note: Dual Targeting of Wild-Type and Mutant p53 by Small-molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro

  2021cites this paper
• Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer

  2021cites this paper
• β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling.

  2021cites this paper
• Expression of Wild-Type p53 by Curcumin, Alpinetin and Flavokawain B in Colorectal Cancer cells Expressing R273H Mutant p53

  2020cites this paper
• Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer.

  2020cites this paper
• Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action

  2020cites this paper
• Exploring the multiple roles of guardian of the genome: P53

  2020cites this paper
• Molecular targeting therapies for neuroblastoma: Progress and challenges

  2020cites this paper
• Current developments of targeting the p53 signaling pathway for cancer treatment.

  2020cites this paper
• Recent Synthetic Approaches towards Small Molecule Reactivators of p53

  2020cites this paper
• Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

  2020influential citation
• Identification and targeting of selective vulnerability rendered by tamoxifen resistance

  2020cites this paper
• Alkaloids of fascaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review.

  2020cites this paper
• JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways.

  2019cites this paper
• RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.

  2019cites this paper
• Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.

  2019cites this paper
• MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.

  2019cites this paper
• Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy

  2019cites this paper
• Mutant p53 in cancer therapy—the barrier or the path

  2018cites this paper
• Awakening the “guardian of genome”: reactivation of mutant p53

  2018cites this paper
• Reviving the guardian of the genome: Small molecule activators of p53

  2017cites this paper
• Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin

  2017cites this paper
• When the guardian sleeps: Reactivation of the p53 pathway in cancer.

  2017cites this paper
• RITA displays anti-tumor activity in medulloblastomas independent of TP53 status

  2017cites this paper
• Molecularly targeted therapies for p53-mutant cancers

  2017cites this paper
• RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems

  2017cites this paper
• Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells

  2017cites this paper
• Correction: Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells

  2017cites this paper
• Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.

  2016cites this paper
• Untersuchung des Effektes von RITA auf das Wachstum von Medulloblastomzellen

  2016cites this paper
• Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma

  2016cites this paper
• Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells

  2016cites this paper
• Chemical Variations on the p53 Reactivation Theme

  2016cites this paper
• The role of p53 in cancer drug resistance and targeted chemotherapy

  2016influential citation
• NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis

  2015cites this paper
• Pharmacological reactivation of p53 as a strategy to treat cancer

  2015cites this paper
• Targeting Oncogenic Mutant p53 for Cancer Therapy

  2015cites this paper
• Neuroblastoma and the p53 Pathway

  2015cites this paper
• Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.

  2015cites this paper
• CRISPR-Cas9-based target validation for p53-reactivating model compounds

  2015cites this paper
• Wild type p53 reactivation: From lab bench to clinic

  2014cites this paper
• Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

  2014cites this paper
• Small molecules that affect the p53 pathway and their potential use in the treatment of cancer

  2014cites this paper
• Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells.

  2014influential citation
• RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38

  2014cites this paper
• Singly protonated dehydronorcantharidin silver coordination polymer induces apoptosis of lung cancer cells via reactive oxygen species-mediated mitochondrial pathway.

  2014cites this paper
• Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents

  2014cites this paper
• p53 Family and Cellular Stress Responses in Cancer

  2014cites this paper
• Dihydromyricetin Reduced Bcl-2 Expression via p53 in Human Hepatoma HepG2 Cells

  2013cites this paper